{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "USD", "regularMarketChangePercent": -0.72832966, "regularMarketPrice": 25.352, "exchange": "LSE", "shortName": "VIRIDIAN THERAPEUTICS INC VIRID", "longName": "Viridian Therapeutics, Inc.", "messageBoardId": "finmb_45015663", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "market": "gb_market", "marketState": "POSTPOST", "esgPopulated": false, "bookValue": 6.123, "fiftyDayAverage": 31.038002, "fiftyDayAverageChange": -5.6860027, "fiftyDayAverageChangePercent": -0.18319488, "twoHundredDayAverage": 26.538778, "twoHundredDayAverageChange": -1.186779, "twoHundredDayAverageChangePercent": -0.044718675, "priceToBook": 4.140454, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "prevName": "Miragen Therapeutics", "nameChangeDate": "2023-05-11", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1517212800000, "priceHint": 2, "regularMarketChange": -0.18600082, "regularMarketTime": 1683732446, "regularMarketDayHigh": 0.0, "regularMarketDayRange": "0.0 - 0.0", "regularMarketDayLow": 0.0, "regularMarketVolume": 4000, "regularMarketPreviousClose": 25.538, "bid": 0.0, "ask": 0.0, "fullExchangeName": "LSE", "financialCurrency": "USD", "regularMarketOpen": 0.0, "averageDailyVolume3Month": 145, "averageDailyVolume10Day": 137, "fiftyTwoWeekLowChange": 25.352, "fiftyTwoWeekRange": "0.0 - 38.51", "fiftyTwoWeekHighChange": -13.157999, "fiftyTwoWeekHighChangePercent": -0.3416775, "fiftyTwoWeekLow": 0.0, "fiftyTwoWeekHigh": 38.51, "earningsTimestamp": 1683664200, "earningsTimestampStart": 1683664200, "earningsTimestampEnd": 1683664200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -5.137, "symbol": "0K1R.L"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "221 Crescent Street", "address2": "Suite 401", "city": "Waltham", "state": "MA", "zip": "02453", "country": "United States", "phone": "617 272 4600", "fax": "617 272 4601", "website": "https://www.viridiantherapeutics.com", "industry": "", "sector": "", "longBusinessSummary": "Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 86, "companyOfficers": [{"maxAge": 1, "name": "Mr. Kristian  Humer M.B.A.", "age": 47, "title": "CFO, Chief Bus. Officer, Principal Financial Officer & Principal Accounting Officer", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": {"raw": 816930, "fmt": "816.93k", "longFmt": "816,930"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 2151703, "fmt": "2.15M", "longFmt": "2,151,703"}}, {"maxAge": 1, "name": "Dr. Barrett  Katz CMO, M.B.A., M.D., MBA", "age": 72, "title": "Chief Medical Officer", "yearBorn": 1950, "fiscalYear": 2022, "totalPay": {"raw": 635616, "fmt": "635.62k", "longFmt": "635,616"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1299404, "fmt": "1.3M", "longFmt": "1,299,404"}}, {"maxAge": 1, "name": "Mr. Scott D. Myers M.B.A.", "age": 56, "title": "Pres, CEO & Director", "yearBorn": 1966, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Eric N. Olson Ph.D.", "title": "Co-Founder & Chairman of Scientific Advisory Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Michael R. Bristow M.D., Ph.D.", "age": 77, "title": "Co-Founder & Member of the Scientific Advisory Board", "yearBorn": 1945, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Marvin H. Caruthers Ph.D.", "age": 82, "title": "Co-Founder & Scientific Advisory Board Member", "yearBorn": 1940, "fiscalYear": 2015, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Vahe  Bedian Ph.D.", "title": "Co-Founder & Scientific Advisor", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Rob  Henderson Ph.D.", "title": "Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Janielle  Newland", "title": "Chief Admin. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Todd  James IRC", "title": "Sr. VP of Corp. Affairs & Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 7, "boardRisk": 5, "compensationRisk": 10, "shareHolderRightsRisk": 6, "overallRisk": 9, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}